A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Inclusion Criteria: * Subjects of either gender aged ≥ 50 years * Diagnosis of Non-foveal GA secondary to dry AMD Exclusion Criteria: * Any prior treatment for AMD (dry or wet) or any prior intravitreal treatment for any indication in either eye, except oral supplements of vitamins and minerals * Any intraocular surgery or thermal laser within 3 months of trial entry. * Any prior thermal laser in the macular region, regardless of indication * Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks. * Previous therapeutic radiation in the region of the study eye * Any sign of diabetic retinopathy in either eye